Review of Prostate Anatomy and Embryology and the Etiology of Benign Prostatic Hyperplasia.
Aaron L, Franco OE, Hayward SW.
Urol Clin North Am. 2016 Aug;43(3):279-88. doi: 10.1016/j.ucl.2016.04.012.
Benign prostate hyperplasia and nutrition.
Das K, Buchholz N.
Clin Nutr ESPEN. 2019 Oct;33:5-11. doi: 10.1016/j.clnesp.2019.07.015. Epub 2019 Aug 12.
Management of Benign Prostatic Hyperplasia.
Kim EH, Larson JA, Andriole GL.
Annu Rev Med. 2016;67:137-51. doi: 10.1146/annurev-med-063014-123902. Epub 2015 Sep 2.
Benign prostatic hyperplasia.
Infante Hernández S, Gómez Rivas J, Moreno Sierra J.
Med Clin (Barc). 2024 Oct 25;163(8):407-414. doi: 10.1016/j.medcli.2024.04.014. Epub 2024 Jul 15.
Benign Prostatic Hyperplasia.
Langan RC.
Prim Care. 2019 Jun;46(2):223-232. doi: 10.1016/j.pop.2019.02.003. Epub 2019 Apr 1.
Benign prostatic hyperplasia - what do we know?
Devlin CM, Simms MS, Maitland NJ.
BJU Int. 2021 Apr;127(4):389-399. doi: 10.1111/bju.15229. Epub 2020 Sep 24.
Recent Advancements in Prostate Catheters and Stents for Management of Benign Prostatic Hyperplasia.
Lama J, Winograd J, Codelia-Anjum A, Bhojani N, Elterman D, Zorn KC, Chughtai B.
Curr Urol Rep. 2024 Oct 7;26(1):9. doi: 10.1007/s11934-024-01235-3.
Benign prostate hyperplasia: a review of the year's progress from bench to clinic.
Donnell RF.
Curr Opin Urol. 2011 Jan;21(1):22-6. doi: 10.1097/mou.0b013e32834100dd.
Management of benign prostate hyperplasia: an overview of alpha-adrenergic antagonist.
Garg G, Singh D, Saraf S, Saraf S.
Biol Pharm Bull. 2006 Aug;29(8):1554-8. doi: 10.1248/bpb.29.1554.
The role of prostate-specific antigen in the evaluation of benign prostatic hyperplasia.
Tchetgen MB, Oesterling JE.
Urol Clin North Am. 1995 May;22(2):333-44.
